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The use and role of allergen immunotherapy (AIT) in asthma is still a matter of debate, and no definite recommendation
about this is made in guidelines, both for the subcutaneous and sublingual routes. This is essentially due to the fact that
most controlled randomised trials were not specifically designed for asthma, and that objective measures of pulmonary
function were only occasionally considered. Nonetheless, in many trials, favourable results in asthma (symptoms,
medication usage, bronchial reactivity) were consistently reported. There are also several meta analyses in favour of AIT,
although their validity is limited by a relevant methodological heterogeneity. In addition to the crude clinical effect, a
disease modifying action of AIT (prevention of asthma onset and long-lasting effects) have been reported. The safety is
an important aspect to consider in asthma. Fatalities were rare: in Europe no fatality was reported in the last three
decades, as in the United States in the last 4 years. Based on previous surveys, and common sense, uncontrolled asthma
is still recognized as the most important risk factor for severe adverse events. On the contrary, there is no evidence that
AIT can worsen or induce asthma. According to the available evidence, AIT can be safely used as add-on treatment
when asthma is associated with rhinitis (a frequent condition), provided that asthma is adequately controlled by
pharmacotherapy. AIT cannot be recommended or suggested as single therapy. When asthma is the unique
manifestation of respiratory allergy, its use should be evaluated case by case.
Keywords: Allergen immunotherapy, Sublingual immunotherapy, Subcutaneous immunotherapy, Efficacy, Safety,
Allergic asthma, Allergic rhinitis, Adverse eventsIntroduction
Considering the systemic mechanisms of action of AIT
[1] and the immunological unity of respiratory airways
[2], it is clear that AIT is not specific for the type of dis-
ease (rhinitis or asthma) but only for the allergen caus-
ing the disease itself [3]. Nonetheless, the efficacy of AIT
has been usually kept separated for asthma and rhinitis,
as testified by meta-analyses, commentaries and guidelines
[4–6]. Indeed, the majority of data available concern clin-
ical trials including patients with allergic rhinitis (AR),
which was the primary outcome measure, with/without
asthma. Consequently, asthma-related parameters, were
either secondary outcomes or subject of post-hoc analyses.
This reflects the clinical practice in real life, where isolated
allergic asthma without rhinitis is infrequent, but asthma
is present in more than 30 % of rhinitis patients, and the* Correspondence: passalacqua@unige.it
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Very few trials were, therefore, specifically designed to
evaluate the effect of SIT in asthma alone, or with asthma
parameters taken as primary outcome. This implies that
few trials were adequately designed and reported, had an
adequate sample size calculation and a power analysis
based on asthma characteristics [7, 8]. In this regard, the
best primary outcome for evaluation asthma in clinical tri-
als is still uncertain and discussed. Asthma symptoms,
asthma-free days, rescue medications usage, days free of
medications, asthma-related quality of life (QoL) and
asthma exacerbations are all reasonable choices [9]. Ob-
jective measures (pulmonary function test, specific and
non-specific bronchial provocation, exhaled nitric oxide)
would be more robust parameters, but they were consid-
ered only sporadically. Keeping in mind those methodo-
logical limitations (Table 1), the main questions are: is
AIT effective in asthma?, is it safe (worsening/precipitat-
ing asthma)? is asthma a risk factor for AIT-related severeess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Main methodological limitations of the studies considering AIT in asthma
ITEM CRITICAL ASPECTS
Patients’ selection Patients should be selected matching asthma severity and, current asthma therapy
Primary outcome Asthma-related parameters should be the primary outcome
Sample size calculation Based on asthma-related primary outcome
Objective parameters Pulmonary function tests/bronchial challenges should be included in primary outcomes
AIT protocol Should be uniformed (duration, doses, run-in etc.)
Duration An optimal duration of the AIT course is not established
Dose The optimal maintenance dose needs to be established for most allergens. Discrepancies among manufacturers
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asthma?
The knowledge on the effects, and safety, of AIT in
asthma is based, in summary, on either historical clinical
trials with SCIT, previous safety surveys and recent trials
with SLIT. All these data, taken together are certainly
not conclusive, but some suggestions applicable in the
clinical practice can be derived [7, 8].
Ait in asthma: the clinical evidence
As mentioned above, in the large majority of clinical tri-
als with SCIT and SLIT, rhinitis was the primary out-
come studied, but in many studies part of the patients
enrolled also suffered from concomitant asthma, thus,
asthma-related outcomes could be analysed (for review
see 3, 6–8).
A certain number of trials expecially with SLIT were,
at some extent, designed to specifically investigate
asthma [10–41], almost all showing significant effects on
asthma symptoms, medications’ usage, or bronchial re-
activity. Some studies specifically assessed the effect of
AIT as inhaled corticosteroids sparing agent in asthma
[21, 29, 37–40]. In the first of the two more recent stud-
ies [37], conducted with SCIT in 65 children for
8 months, a mean 50 % reduction in the dose of inhaled
fluticasone was seen in the active group, who remainedTable 2 Meta analyses of AIT in ashtma
Author, Year (REF) Type of AIT Studies PATS
Abramson, 2010 [42] SCIT 34 symptoms 727/5
20 medications 485/3
Erekoshima 2013 [43] SCIT 10 symptoms 320/3
8 medications 285/2
Calamita, 2007 [44] SLIT 9 symptoms 150/1
6 medications 132/1
Penagos, 2008 [45] SLITab 9 symptoms 232/2
7 medications 192/1
Compalati, 2009 [46] SLIT mite 9 symptoms 243/2
7 medications 102/1
aActive/Placebo; abonly children: abcStandardized mean deviationcontrolled. The other one [38] investigated 3 doses of
SLIT in more than 600 adults for 1 year. With the high-
est dose, a significant reduction in mcg of corticosteroids
was seen (p = 0.004) and the relative mean reduction was
42 %. The less recent studies involved smallest samples
[21, 29, 39, 40]: overall demonstrated a steroid-sparing ef-
fect of AIT in asthma, but the extent of this effect was
largely variable, and sometimes of uncertain clinical rele-
vance. Finally, Marogna et al. [41] compared the effect, as
add-on treatment, of inhaled budesonide and SLIT, and
found that over a 3-year period, SLIT was overall more ef-
fective than budesonide in reducing symptoms and bron-
chial hyperreativity. Of note, some studies [11, 13, 21, 33,
34] reported only marginal effects on asthma, but in two
of these studies all the patients (active and controls) had
almost no asthma at baseline and during the trial [33, 34].
Despite the important limitations (small sample, no power
calculation, variable inclusion criteria) the published stud-
ies substantially agree on the clinical efficacy of SCIT in
asthma, induced by the most common allergens (grass,
mite, pet dander).
Based on the results of the trials, several meta-analyses
were conducted (Table 2). The largest available meta-
analysis of SCIT in asthma [42] included 88 trials (70
randomized and placebo controlled, but only few with
symptoms and medications clearly reported). The(A/P)a Results (effect size, 95 % C.I.)
57 Symptoms −0.6 (−0.83 -0.35) significant
84 Medications −0.5 (−08 -0.3) significant
08 Strength of evidence reported as “high” for both outcomes
88
53 Symptoms −0.38 (−0.79 0.03) not significant
22 Medications −0.9 (−1.9 -0.12) significant
09 Symptoms −1.18 (−2.1 -018) significant
74 Medication −1.63 (−2.8 -044) significant
09 Symptoms SMD 0.95 (1.74 0.15) significantabc
00 Medications SMD 1.48 (2.70 0.26) significant
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moderate, with only 6 trials receiving the maximum of
5 points at the Jadad score), the concealment of alloca-
tion was considered adequate in 16 trials, symptoms
scores were reported in 35 studies and medications in
21. Only 20 studies included pulmonary function mea-
surements. According to this analysis, the reduction of
symptoms with mite allergens remained borderline,
whereas the effect was highly significant with pollens
and, in general for asthma medications. No change in
pulmonary function was appreciable, but a significant
improvement at the allergen-specific bronchial chal-
lenge. The heterogeneity of the studies was high, thus
limiting the strength of the conclusions. Another system-
atic review, considering only the USA-licensed products
for SCIT (15 trials with asthma symptoms reported, 790
patients) concluded there was strong evidence for efficacy
of the treatment [43]. Concerning SLIT, there are two
meta analyses: one including all age classes (25 random-
ized double blind trials, 1076 patients) [44] and one lim-
ited to pediatric subjects (9 studies, 441 patients) [45].
Both analyses confirmed the presence of a measurable
effect over placebo. Nonetheless, the first metaanalysis
showed no significant difference between SLIT and pla-
cebo when asthma symptoms and asthma medications
were considered separately. was negative for some param-
eters [44]. One of the major problems of meta-analyses is
that they pool together studies conducted with different
allergens (i.e. mites and pollens). This aspect could be bet-
ter addressed for SLIT due to the abundance of studies,
restricting the analysis to mite extracts [46] or to grass
extracts [47]. The meta-analysis for dust mites included
9 trials that evaluated asthma symptoms and medica-
tions. It showed a significant reduction versus placebo
in symptom scores (p = 0.02) and medications (p = .02).
The meta analysis for grasses did not report specific re-
sults for asthma.
There is still some debate about the comparison of
efficacy between SLIT and SCIT. No study specifically
addressed the problem for asthma, but a comprehen-
sive view of the meta analyses suggest that the efficacy
is overall the same [48]. Similarly, there is no study in
asthma comparing the effects of AIT and drugs. Rak
et al. [49] demonstrated the superiority of nasal corti-
costeroids versus AIT in rhinitis but found that AIT
only could decrease the seasonal bronchial hyperreac-
tivity in asthmatic patients and Sheikh et al. evidenced
the persisting effect of SCIT over inhaled steroids
after discontinuation [50]. Another trial [51] in asth-
matic children showed that adding AIT to inhaled
fluticasone did not cause a further improvement of
symptoms, but SLIT only decreased non-bronchial
symptoms. Finally, an open randomized trial of SLIT
(as add-on treatment) versus inhaled budesonide alonein asthmatic patients, demonstrated an overall super-
iority of AIT over time [41]. All these studies that
were not randomized, properly powered or were de-
signed as open trials limits the methodological value
of the observations.
Safety aspects of ait in asthma
AIT implies the administration of extracts of substances
(allergens) to which the subject is sensitized. This can
lead to adverse reactions, that can be either local or sys-
temic (SRs), this latter, spanning until anaphylaxis and
death. The reported occurrence of SRs is largely variable,
according to allergen, induction schedule, preparation
and dose. The available data (on large populations) come
from the surveys regularly performed in the USA with
SCIT which [52, 53], reported about 50 deaths over a
50-year period with a risk of one death every 2.500.000
injections and one near-fatal reaction per million injec-
tions. Human errors and uncontrolled asthma were the
most frequent causes of SCIT-induced adverse events
[53, 54]. On the other hand, in the period 2008–2011 no
further fatality due to SCIT was reported in the United
States and SRs were about 0.1 % of injection visits [55].
Evaluating those data, it must be kept in mind that the
practice of SCIT profoundly differs between Europe and
United States, where allergen mixes and higher concen-
trations are commonly used [56]. Few systematic data is
available in European countries [57, 58]. A recent multi-
center observational study [59] suggested that systemic
reactions are slightly more frequent in rhinitis with
asthma than in rhinitis patients alone. According to the
past observations and the few recent data, the scientific
community agreed, as a prudential attitude, to consider
uncontrolled/severe asthma as a major risk factor for se-
vere adverse events of AIT [3, 5]. Despite no direct ob-
servation has been published, this attitude has been
translated also to SLIT [6]. In this regard, the safety of
SLIT is overall superior to that of SCIT [6, 60], at least
because no fatality has been reported until now, and
only few cases of suspect/ascertained anaphylaxis have
been described, none directly attributable to pre-existing
asthma or to worsening of asthma [61]. The potential of
precipitating asthma has been considered in some stud-
ies A controlled dose-finding study of safety [62] involv-
ing 48 grass-allergic patients outside the pollen season
and receiving up to 200 mcg Phl p 5, (about 40 times
the SCIT dose) showed an incidence of side effects of
74 %, all of which were mild or moderate in intensity
and all localized. Dahl et al. [34] assessed the safety of
SLIT in asthma in more than 100 grass-allergic asth-
matics. The number of side effects possibly linked to
asthma (wheezing cough, dyspnoea) was similar between
the active and placebo group, and there was no evidence
of asthma aggravation.
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controlled asthma remains the main risk factor for side ef-
fects due to AIT, although for SLIT severe asthma have
been not clearly demonstrated as a specific contraindication.
In general, asthma is not an absolute contraindication to
AIT, if the patient is well controlled with pharmacotherapy.
As a future perspective, an uniform reporting and grad-
ing of side effects would be desirable. This has recently
been addressed by the World Allergy Organization, which
proposed a grading system for systemic reactions due to
SCIT/SLIT [63] and for local reactions due to SLIT [64].
Disease-modifying effects
Rhinitis is the most important independent risk factor
for the development of asthma [1, 65], and in the natural
history, usually rhinitis precedes asthma. AIT is an im-
mune response modifier, thus it was hypothesized that it
may alter the progression of the disease, reducing the
risk of asthma onset. The preventive effect of AIT on
the risk of developing asthma was quantified in some
controlled trials only during the last decades. The Pre-
ventative Allergy Treatment study enrolled 205 children
(aged 6–10 years) suffering from allergic rhinitis, and
randomized to either drug therapy alone or drugs plus
SCIT. After 3 years, the SCIT-treated patients developed
significantly less asthma than the control group (odds
ratio 2.5) [66]. The beneficial effect of SCIT lasted at
least 7 years after discontinuation [67]. The same effect
was demonstrated with SLIT. The first open controlled
study [68] involved 113 children aged 5–14 years with
seasonal rhinitis due to grass pollen, randomly allocated
to medications plus SLIT or medications only. After
3 years, 8/45 SLIT subjects and 18/44 controls had de-
veloped asthma, with a relative risk of 3.8 for untreated
patients. The other randomized open controlled trial
[69] involved 216 children (5–17 years) suffering from
rhinitis with/without intermittent asthma, randomly al-
located 2:1 to drugs plus SLIT or drugs only. The preva-
lence of persistent asthma after 3 years of observation
was 1.5 % in the SLIT group and 30 % for the control
group.
It is true that there are only 3 studies addressing the pre-
ventive effect of AIT, involving less than 300 patients in
total. Nonetheless, due to the relevance of this aspect, new
trials with rigorous methodology are currently ongoing,
such as the GAP study [70], which is involving more than
800 children in a 5-year double blind evaluation.
Conclusions
The literature on the clinical and immunological effects of
AIT is abundant, and many guidelines and recommenda-
tions were prepared according to structured evaluation
systems such as the GRADE [71]. According to GRADE
the essential requirement is that the methodology of thestudy is adequate (e.g. sample size, outcome, selection cri-
teria, randomization), that is not always the case for AIT
in asthma (Table 1), since many of the randomized
controlled trials had important limitations (small num-
ber of patients, no objective measurement of respiratory
function, no sample size calculation based on the objective
parameters, variability of doses and protocols). This facts
burden the meta-analyses, where the positive clinical re-
sults are counterbalanced by the high heterogeneity of the
studies.
Indeed, beyond the methodological limitations, there
is an abundant experimental evidence that AIT is effect-
ive in controlling symptoms and medications intake in
patients with asthma (usually concomitant to rhinitis)
[72]. Thus, it should be confidently stated that SLIT and
SCIT can be used together with asthma medications,
when asthma is associated to rhinitis and the causal role
of the allergen is clearly confirmed. Also when asthma is
the only allergic disease (that is rare), AIT is expected to
exert a beneficial effect. It does not seem that AIT can
worsen asthma, whereas uncontrolled asthma remains a
significant risk factor for adverse events. The disease-
modifying effects of AIT in asthma prevention should be
taken into account [73], although there are so far only 3
studies on this aspect. On the other hand, the cautious
attitude towards the use of AIT in asthma is testified by
the fact that the recently FDA approved products (tablet
SLIT for ragweed and grass) do not have the indication
for asthma, but only for rhinoconjunctivitis.
Overall, it has to be considered that asthma is per
se a heterogeneous disease, with different endotypes
[74] and different types of underlying inflammation.
In addition, allergens are often but not always the
unique triggers of the inflammatory reation. These
facts can explain the variable efficacy of antinflamma-
tory treatments, allergen avoidance strategies, and
AIT itself. So far, an unequivocal biomarker capable
of predicting the response to treatments has not been
yet identified [75].
Main unresolved questions and unclear aspects are the
optimal maintenance dose to use, the duration of treat-
ment to obtain a satisfactory long term effect, and the
appropriate use of objective outcomes. Probably, the
most important questions are which children with rhin-
itis should receive AIT to prevent the future develop-
ment of asthma, and which biomarkers are relevant to
identify the potential responders.
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